Article

Anecortave acetate: possible new treatment for glaucoma?

Anecortave acetate (Retaane, Alcon Laboratories) is a potential newtherapy for glaucoma that seems to be highly effective, with a mean25% decrease in IOP 6 months after one juxtascleral injection.

Anecortave acetate (Retaane, Alcon Laboratories) is a potential new therapy for glaucoma that seems to be highly effective, with a mean 25% decrease in IOP 6 months after one juxtascleral injection.

Alan Robin, MD, of the department of ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, reported the results of a nonrandomized, open-label trial of anecortave acetate in six patients.

"Anecortave acetate is a steroid that lowers IOP," Dr. Robin said.

While anecortave acetate is similar to tetrahydrocortisol, modifications - such as the removal of the 11-hydroxyl OH group, introduction of the C9-11 double bond, and addition of a 21-acetate group - result in the absence of the anti-inflammatory and immunosuppressive properties of glucocorticoids, he explained.

Patients (mean age, 59 years) received one injection of anecortave acetate (0.8 ml of the 3% solution). The injections were given over 1 minute. The patients were followed at 1 hour and 1 week, and then weekly for 1 month and monthly for 6 months. The patients all had an IOP level that exceeded 23 mm Hg (range, 23 to 56) despite topical anti-glaucoma medications. The mean IOP before treatment was almost 31 ± 11.3 mm Hg. Four patients had primary open-angle glaucoma (n = 4), pseudoexfoliation syndrome (n = 1), and pigmentary dispersion syndrome (n = 1).

"Five of the six patients had an IOP decrease of 25% or greater 3 months after the injection," Dr. Robin said. "The mean IOP after treatment was 16.4 ± 6 mm Hg."

IOP decreased from 25 to 12 mm Hg in one patient 2 months after treatment and decreased from 25 to 15 mm Hg in another patient 4 months after treatment. In both cases, the prostaglandin they were taking was stopped. The patient with pigmentary dispersion syndrome did not respond to anecortave acetate.

In addition to the sustained decrease in IOP, Dr. Robin pointed out the delivery system may be an answer to administration of eye drops, which can be problematic in some patients.

Studies are under way to determine the mechanism of action of anecortave acetate in the lowering of IOP.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.